Validation of Serum Amyloid alpha as an Independent Biomarker for Progression-Free and Overall Survival in Metastatic Renal Cell Cancer Patients

J.S. Vermaat, F.L. Gerritse, A.A. van der Veldt, W.M. Roessingh, T.M. Niers, S.F. Oosting, S. Sleijfer, J.M. Roodhart, J.H. Beijnen, J.H. Schellens, J.A. Gietema, E. Boven, D.J. Richel, J.B. Haanen, E.E. Voest

Research output: Contribution to journalArticleAcademicpeer-review

Original languageUndefined/Unknown
Pages (from-to)685-695
JournalEuropean Urology
Volume62
Issue number4
DOIs
Publication statusPublished - 2012

Cite this

Vermaat, J. S., Gerritse, F. L., van der Veldt, A. A., Roessingh, W. M., Niers, T. M., Oosting, S. F., ... Voest, E. E. (2012). Validation of Serum Amyloid alpha as an Independent Biomarker for Progression-Free and Overall Survival in Metastatic Renal Cell Cancer Patients. European Urology, 62(4), 685-695. https://doi.org/10.1016/j.eururo.2012.01.020